The U.S. Food and Drug Administration granted Roche’s Venclexta (venetoclax) full approval in combination with azacytidine, or decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia in adults 75 years or older.
https://www.pharmalive.com/wp-content/uploads/2020/10/Roches-Venclexta-Granted-Full-Approval-Under-Project-Orbis-and-Real-Time-Review-BioSpace-10-19-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-10-19 12:21:412020-10-19 12:32:23Roche’s Venclexta Granted Full Approval Under Project Orbis and Real-Time Review